Question · asked by 1 review
Summary of findings: monoclonal antibody KB001‐A vs placebo: Pulmonary exacerbations
- Population
- children (12 or over) and adults with cystic fibrosis and lung infection
- Intervention
- Summary of findings: monoclonal antibody KB001‐A
- Comparison
- placebo
- Outcome
- Pulmonary exacerbations
Summary of findings: monoclonal antibody KB001‐A showed no clear difference in pulmonary exacerbations compared with placebo (low certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Summary of findings: monoclonal antibody KB001‐A vs placebo Pulmonary exacerbations · children (12 or over) and adults with cystic fibrosis and lung infection Summary of findings: monoclonal antibody KB001‐A showed no clear difference in pulmonary exacerbations compared with placebo (low certainty). Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis (2020) · Cochrane Headline outcomes only | RR 0.25 [0.03, 2.4] | 2 studies · 196 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.